Cover art for US FDA rejects lung cancer drug from China

US FDA rejects lung cancer drug from China

US FDA rejects Chinese lung cancer drug after trial shows no life extension.

Nov 16, 2026

3 cards · 50s · tap to begin

From · · 50s

US FDA rejects lung cancer drug from China

US FDA rejects Chinese lung cancer drug after trial shows no life extension.

In brief

US FDA rejects Chinese lung cancer drug after trial shows no life extension. US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma, after clinical trials failed to show statistically significant life extension. Originally reported by The Straits Times.

FDA rejection

US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma and licensed by Summit Therapeutics, after clinical trials failed to show statistically significant life extension.

Drug development setback

Summit Therapeutics disclosed the FDA's decision on Nov 15, 2026, after buying US rights from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories.

Market impact

Market impact

The rejection weakens hopes that ivonescimab could rival Keytruda, though the drug is still being tested in other cancers such as colon, bladder and breast.

What to remember

US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma, after clinical trials failed to show statistically significant life extension.

Read the original on The Straits Times

Read the TL;DR — this story on one card.

More news from China

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on us food and drug administration and related topics.